ADVIA® Chemistry ALT_c, ALT (GPT) Reagents, Concentrated 10283341Recalls & reported problems
Siemens Healthcare Diagnostics Inc. · ALT/GPT - ADVIA Chem. - Conc. RGT - 6x850 tests · Class 1
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 00630414553139), received between Jun 22, 2023 and Jun 22, 2023 — classified as 2 malfunctions.
The most frequently reported specific device problem is “Incorrect, Inadequate or Imprecise Result or Readings” (2 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Incorrect, Inadequate or Imprecise Result or Readings2
Patient problems
- No Clinical Signs, Symptoms or Conditions2
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
MalfunctionJun 22, 2023Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings
THE CUSTOMER ALLEGED THAT DUE TO VARIABLE ALANINE AMINOTRANSFERASE (ALT) RESULTS OBTAINED ON A PATIENT SAMPLE ON TWO ADVIA CHEMISTRY XPT INSTRUMENTS (IDENTIFIED AS CA1275001960196 AND CA1275001970197) USING ADVIA CHEMISTRY CONCENTRATED ALANINE AMINOTRANSFERASE (ALT_C) REAGENT, THE CUSTOMER DELAYED REPORTING OTHER TESTS ORDERED ON THE SAMPLE; THE CLINICIAN ALLEGED THE DELAY IN REPORTING RESULTS WAS A FACTOR THAT AFFECTED THE CARE OF A CLINICALLY DETERIORATING PATIENT. THE LABORATORY WAS RELEASING RESULTS FOR OTHER PATIENTS DURING THIS TIME. THE CUSTOMER REPORTED THAT AT THE TIME OF THE EVENT, BLOOD GAS RESULTS FROM ANOTHER INSTRUMENT WERE AVAILABLE TO THE CLINICIAN AND CALCIUM/MAGNESIUM AND SALINE IV WERE UNDERWAY. SINCE THE CUSTOMER DID NOT RELEASE THE UREA NITROGEN AND CREATININE RESULTS, THE CLINICIAN DID NOT HAVE THESE RESULTS FROM THE ADVIA CHEMISTRY XPT INSTRUMENTS. IT IS UNKNOWN WHY THE LABORATORY DID NOT PROMPTLY RELEASE THE RESULTS TO THE CLINICIANS. THE SAMPLE WAS COLLECTED AT 11:00 PM ON (B)(6) 2023 AND ARRIVED AT THE LABORATORY AT 11:03 PM ON (B)(6) 2023. THE UNFLAGGED RESULTS FOR ALL THREE ANALYTES, ALT, UREA NITROGEN AND CREATININE, WERE AVAILABLE AT 11:34 PM ON (B)(6)
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 17183296 ↗MalfunctionJun 22, 2023Incorrect, Inadequate or Imprecise Result or Readings; Incorrect, Inadequate or Imprecise Result or Readings
THE CUSTOMER ALLEGED THAT DUE TO VARIABLE ALANINE AMINOTRANSFERASE (ALT) RESULTS OBTAINED ON A PATIENT SAMPLE ON TWO ADVIA CHEMISTRY XPT INSTRUMENTS (IDENTIFIED AS CA1275001960196 AND CA1275001970197) USING ADVIA CHEMISTRY CONCENTRATED ALANINE AMINOTRANSFERASE (ALT_C) REAGENT, THE CUSTOMER DELAYED REPORTING OTHER TESTS ORDERED ON THE SAMPLE; THE CLINICIAN ALLEGED THE DELAY IN REPORTING RESULTS WAS A FACTOR THAT AFFECTED THE CARE OF A CLINICALLY DETERIORATING PATIENT. THE LABORATORY WAS RELEASING RESULTS FOR OTHER PATIENTS DURING THIS TIME. THE CUSTOMER REPORTED THAT AT THE TIME OF THE EVENT, BLOOD GAS RESULTS FROM ANOTHER INSTRUMENT WERE AVAILABLE TO THE CLINICIAN AND CALCIUM/MAGNESIUM AND SALINE IV WERE UNDERWAY. SINCE THE CUSTOMER DID NOT RELEASE THE UREA NITROGEN AND CREATININE RESULTS, THE CLINICIAN DID NOT HAVE THESE RESULTS FROM THE ADVIA CHEMISTRY XPT INSTRUMENTS. IT IS UNKNOWN WHY THE LABORATORY DID NOT PROMPTLY RELEASE THE RESULTS TO THE CLINICIANS. THE SAMPLE WAS COLLECTED AT 11:00 PM ON (B)(6) 2023 AND ARRIVED AT THE LABORATORY AT 11:03 PM ON (B)(6) 2023. THE UNFLAGGED RESULTS FOR ALL THREE ANALYTES, ALT, UREA NITROGEN AND CREATININE, WERE AVAILABLE AT 11:34 PM ON (B)(6)
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 17183233 ↗
Other NADH OXIDATION/NAD REDUCTION, ALT/SGPT devices
- Alanine Aminotransferase acc. to IFCC with pyridoxal phosphate activation 08056773190Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT10 reports
- Alanine Aminotransferase acc. to IFCC II 08104697190Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT7 reports
- Alanine Aminotransferase acc. to IFCC without pyridoxal phosphate activation 20764957322Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT6 reports
- Alanine Aminotransferase acc. to IFCC without pyridoxal phosphate activation 5850797190Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT3 reports
- Alanine Aminotransferase acc. to IFCC with pyridoxal phosphate activation 4467388190Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT2 reports
- ARCHITECT 8L92-21Abbott Laboratories · NADH OXIDATION/NAD REDUCTION, ALT/SGPT1 report
- ARCHITECT 8L92-41Abbott Laboratories · NADH OXIDATION/NAD REDUCTION, ALT/SGPT1 report
- Alanine Aminotransferase / Aspartate Aminotransferase acc. to IFCC with PYP 5531462190Roche Diagnostics GmbH · NADH OXIDATION/NAD REDUCTION, ALT/SGPT1 report
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page